Biotech · Private company · Austin, TX, US
Molecular Templates, Inc.
SEC CIK 0001183765
Track this companyFree. Adds Molecular Templates, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials80 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- GemcitabinePhase 2 · Non-hodgkin Lymphoma,B CellClinicalTrials.gov · fetched Nov 12, 2026
- MT-3724Phase 2 · Non-hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- MT-3724Phase 2 · Non-hodgkin Lymphoma,B CellClinicalTrials.gov · fetched Nov 12, 2026
- MT-3724 Phase 1Phase 2 · Non-Hodgkin's B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- MT-3724 Phase 2Phase 2 · Non-Hodgkin's B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- OxaliplatinPhase 2 · Non-hodgkin Lymphoma,B CellClinicalTrials.gov · fetched Nov 12, 2026
- MT-0169Phase 1 · Relapsed and/or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- MT-5111 (experimental study drug)Phase 1 · HER2-positive Solid CancersClinicalTrials.gov · fetched Nov 12, 2026
- MT-6402Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- MT-8421Phase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- MT-3724Non-Hodgkin's B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesPHASE1 · TERMINATED · started Nov 1, 2023ClinicalTrials.gov NCT06034860 · fetched Nov 12, 2026
- Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1PHASE1 · TERMINATED · started May 27, 2021ClinicalTrials.gov NCT04795713 · fetched Nov 12, 2026
- A Study of MT-0169 in Participants With Relapsed or Refractory Multiple MyelomaPHASE1 · TERMINATED · started Feb 5, 2020ClinicalTrials.gov NCT04017130 · fetched Nov 12, 2026
- Study of MT-5111 in HER2-positive Solid TumorsPHASE1 · TERMINATED · started Nov 12, 2019ClinicalTrials.gov NCT04029922 · fetched Nov 12, 2026
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)PHASE2 · TERMINATED · started Apr 8, 2019ClinicalTrials.gov NCT03645395 · fetched Nov 12, 2026
- PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's LymphomaPHASE2 · TERMINATED · started Aug 20, 2018ClinicalTrials.gov NCT03488251 · fetched Nov 12, 2026
- Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCLPHASE1_PHASE2 · TERMINATED · started Feb 1, 2015ClinicalTrials.gov NCT02361346 · fetched Nov 12, 2026
- Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell LymphomaNO_LONGER_AVAILABLEClinicalTrials.gov NCT02715843 · fetched Nov 12, 2026
SEC filings7
- 8-KSEC EDGAR · filed Apr 24, 2025 · fetched Nov 12, 2026
- 8-KSEC EDGAR · filed Feb 26, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 2, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 19, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 4, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 4, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 26, 2024 · fetched Nov 12, 2026